Cholesterol, statins, and longevity from age 70 to 90 years

Journal of the American Medical Directors Association

Volumn 14, Issue 12, 2013, Pages 883-888

  Jacobs, Jeremy M ^a   Cohen, Aaron ^a,b   Ein Mor, Eliana ^a   Stessman, Jochanan ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b MINISTRY OF HEALTH   (Israel)

Author keywords

Cholesterol; Longevity; Longitudinal cohort study; Oldest old; Statins

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SERUM ALBUMIN; TRIACYLGLYCEROL;

AGE DISTRIBUTION; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; BODY MASS; CEREBROVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DIABETES MELLITUS; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; LONGEVITY; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; MORTALITY; PREVALENCE; SMOKING; VERY ELDERLY;

CHOLESTEROL; LONGEVITY; LONGITUDINAL COHORT STUDY; OLDEST OLD; STATINS;

AGED; AGED, 80 AND OVER; CHOLESTEROL; COHORT STUDIES; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; ISRAEL; KAPLAN-MEIER ESTIMATE; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; LONGEVITY; LONGITUDINAL STUDIES; MALE; MORTALITY; PROPORTIONAL HAZARDS MODELS; TRIGLYCERIDES;

EID: 84897106858     PISSN: 15258610     EISSN: 15389375     Source Type: Journal    
DOI: 10.1016/j.jamda.2013.08.012     Document Type: Article

References (26)

1. Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Adult treatment panel III, final report. Updated 2004. Available at: Accessed March 7,2013. http://www.nhlbi.nih.gov/guidelines/cholesterol/atp3full.pdf.
2. Grundy S.M., Cleeman J.I., Neol Bairey Merz C., et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation 2004, 110:227-239.
3. Abramson J., Wright J.M. Are lipid-lowering guidelines evidence-based?. Lancet 2007, 369:168-169.
4. Petersen L.K., Christensen K., Kragstrup J. Lipid-lowering treatment to the end? A review of observational studies and RCTs on cholesterol and mortality in 80+-year olds. Age Ageing 2010, 39:674-680.
5. Morley J.E. The cholesterol conundrum. JAm Geriatr Soc 2011, 59:1955-1956.
6. Stessman J., Cohen A., Ginsberg G.M., et al. The Jerusalem 70-year-old longitudinal study. I: Description of the initial cross sectional survey. Eur J Epidemiol 1995, 11:675-684.
7. Jacobs J.M., Cohen A., Bursztyn M., et al. Cohort profile: The Jerusalem longitudinal cohort study. Int J Epidemiol 2009, 38:1464-1469.
8. Jacobs J.M., Maaravi Y., Cohen A., et al. Changing profile of health and function from age 70 to 85 years. Gerontology 2012, 58:313-321.
9. Cohen A., Stessman J., Ginsberg G.M., et al. Jerusalem 70-year-old longitudinal study II: Background results from the initial home interview. Eur J Epidemiol 1995, 11:685-692.
10. Stessman J., Hammerman-Rozenberg R., Cohen A., et al. Physical activity, function, and longevity among the very old. Arch Intern Med 2009, 169:1476-1483.
11. Katz S., Ford A.B., Moskowitz R.W., et al. Studies of illness in the aged. The index of ADL: A standardized measure of biological and psychosocial function. JAMA 1963, 185:914-919.
12. Stessman J., Hammerman-Rozenberg R., Maaravi Y., Cohen A. The impact of exercise on ease of performance of ADL and IADL from age 70-77: The Jerusalem longitudinal study. JAm Geriatr Soc 2002, 50:1934-1938.
13. Folstein M.F., Folstein S.E., McHugh P.R. Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. JPsychiatr Res 1975, 12:189-198.
14. Derogatis L.R., Melisaratos N. The Brief Symptom Inventory: An introductory report. Psychol Med 1983, 13:596-605.
15. Jacobs J.M., Ein-Mor E., Stessman J., Bursztyn M. Hypertension in community dwelling subjects aged 85 years: Is it a mortality risk factor?. JAm Med Dir Assoc 2013, 13:759.
16. International Classification of Diseases, Ninth Revision (ICD-9) 1977, World Health Organization, World Health Organization, Geneva, Switzerland.
17. Charlson M.E., Pompei P., Ales K.L., MacKenzie C.R. Anew method of classifying prognostic comorbidity in longitudinal studies: Development and validation. JChronic Dis 1987, 40:373-383.
18. Efficacy and safety of cholesterol-lowering treatment: Prospective meat-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 2005, 366:1267-1278. Cholesterol Treatment Trialist (CTT) Collaborators.
19. Ali R., Alexander K.P. Statins for the primary prevention of cardiovascular events in older adults: A review of the evidence. Am J Geriatr Pharmacother 2007, 5:52-63.
20. Newson R.S., Felix J.F., Heeringa J., et al. Association between serum cholesterol and noncardiovascualr mortality in older age. JAm Geriatr Soc 2011, 59:1779-1785.
21. de Ruijter W., Westendorp R., Assendelft W., et al. Use of Framingham risk score and new biomarkers to predict cardiovascular mortality in older people: population based observational cohort study. BMJ 2009, 338:a3083.
22. Scuteri A., Lakatta E.G. Bringing prevention in geriatrics: Evidence from cardiovascular medicine supporting the new challenge. Exp Gerontol 2013, 48:64-68.
23. Libby P., Lorenzatti A.J., MacFadyen J.G., et al. Rosuvastatin to prevent vascular events in men and women with elevated c-reactive protein. NEngl J Med 2008, 359:2195-2207.
24. Olivieri F., Mazzanti I., Abbatecola A.M., et al. Telomere/Telomerase system: A new target of statins pleiotropic effect?. Curr Vasc Pharmacol 2012, 10:216-224.
25. Nielsen S.F., Nordestgaard B.G., Bojesen S.E. Statin use and reduced cancer-related mortality. NEngl J Med 2012, 367:1792-1802.
26. Collerton J., Davies K., Jagger C., et al. Health and diseases in 85 year olds: Baseline findings from the Newcastle 85+ cohort study. BMJ 2009, 399:b4904.